Meta AnalysisID 4724
降尿酸治疗对合并无症状高尿酸血症的慢性肾脏病患者肾功能和心肾结局的影响：一项系统评价与Meta分析
CRD42022321527
To evaluate the effects of uric acid lowering therapy on renal function and cardiorenal outcome in patients with chronic kidney disease complicated with asymptomatic hyperuricemia . P: patients with chronic kidney diseas
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4724
- Evidence Id
- 13282
- Core Evidence Id
- 13282
- Source Meta Analysis Id
- 4694
- Herb2 Meta Analysis Id
- HBMA004694
- Crd Id
- CRD42022321527
- Title
- Effects of uric acid lowering therapy on renal function and cardiorenal outcome in patients with chronic kidney disease complicated with asymptomatic hyperuricemia：a systematic review and meta-analysis
- Review Question
- To evaluate the effects of uric acid lowering therapy on renal function and cardiorenal outcome in patients with chronic kidney disease complicated with asymptomatic hyperuricemia . P: patients with chronic kidney disease complicated with asymptomatic hyperuricemia I: uric acid lowering therapy，such as allopurinol and febuxostat C: placebo or blank control or routine treatment O: changes of eGFR or Scr and outcome of cardiovascular events, end-stage renal disease (ESRD), acute renal function decline or doubling of serum creatinine S: randomised controlled trial（RCT）
- Study Type Included
- We will include randomised trials to assess the effects of uric acid lowering therapy on renal function and cardiorenal outcome in patients with chronic kidney disease complicated with asymptomatic hyperuricemia
- Condition Being Studied
- uric acid lowering therapy.renal function.cardiorenal outcome. asymptomatic hyperuricemia.chronic kidney disease.allopurinol.febuxostat.
- Participant
- Inclusion criteria: (1) Research object: adults patients with chronic kidney disease complicated with asymptomatic hyperuricemia . Chronic kidney disease is defined according to KDOQI guidelines or by the author; (2) Intervention measures: only the experimental group was given uric acid lowering treatment, while the control group was given placebo or blank control or general non-uric acid lowering treatment; (3) Research type: randomized controlled trial; (4) Measurement indicators: the study reported the change of glomerular filtration rate or serum creatinine or urine protein, the incidence of renal function deterioration or terminal renal disease or death or cardiorenal outcome. Exclusion criteria: (1) patients with acute renal damage, renal cell carcinoma, end-stage renal disease such as dialysis or renal transplantation; (2) hyperuricemia caused by tumor, malignant hematological disease or rhabdomyolysis syndrome; (3) gouty arthritis or uric acid calculi.
- Animal
- Human Disease Modelled
- Intervention
- Interventions: There are three types of uric acid-lowering drug treatment options: a. Drugs that inhibit uric acid production, such as allopurinol, febuxostat; b. Drugs that promote uric acid excretion, such as benzbromarone;c. Novel uric acid-lowering drugs, such as rasburicase , Purikexi.These drugs have been recognized to reduce the concentration of uric acid in the blood and reduce the deposition of uric acid in the bones, joints or kidneys.
- Comparator Control
- the control group was given placebo or blank control .
- Main Outcome
- changes of eGFR or Scr from baseline to the last available follow-up, outcome of cardiovascular events, end-stage renal disease (ESRD), acute renal function decline or doubling of serum creatinine Measures of effect mean difference, relative risks
- Outcome Measure
- Additional Outcome
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Acid
- Contact
- Song Qirong [email protected]
- Organisational Affiliation
- Southern Medical University https://www.smu.edu.cn/
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- This review is an update of a earlier systematic review and meta-analysis and is being undertaken in the light of the publication of significant new research which will assist in providing evidence based medical evidence for the treatment of chronic kidney disease complicated with asymptomatic hyperuricemia .
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-03-28
- Registration Date
- 2022-04-28
- Anticipated Start Date
- 2021-10-10
- Anticipated Completion Date
- 2022-07-20
- Title Cn
- 降尿酸治疗对合并无症状高尿酸血症的慢性肾脏病患者肾功能和心肾结局的影响：一项系统评价与Meta分析
- Title En
- Effects of uric acid lowering therapy on renal function and cardiorenal outcome in patients with chronic kidney disease complicated with asymptomatic hyperuricemia：a systematic review and meta-analysis
- Bilingual Status
- complete